@article{oai:nagasaki-u.repo.nii.ac.jp:00027373,
 author = {Hirano, Minato and Sakurai, Yasuteru and Urata, Shuzo and Kurosaki, Yohei and Yasuda, Jiro and Yoshii, Kentaro},
 journal = {Antiviral Research},
 month = {Mar},
 note = {Crimean-Congo hemorrhagic fever virus (CCHFV) belongs to the genus Orthonairovirus and is the causative agent of a viral hemorrhagic disease with a case fatality rate of 30%. However, limited studies have been conducted to explore antiviral compounds specific to CCHFV. In this study, we developed a minigenome system of orthonairoviruses, CCHFV and Hazara virus to analyze viral replication and screened an FDA-approved compound library. The transfection of the minigenome components induced marked increase in luciferase expression, indicating the sufficient replication and translation of reporter RNA. Compound library screening identified 14 candidate compounds that significantly decreased luciferase activity. Some of the compounds also inhibited the replication of the infectious Hazara virus. The mechanism of inhibition by tigecycline was further analyzed, and a decrease in the interaction between the viral N protein and RNA by tigecycline was observed. This work provides a basis for validation using animal models and the design of chemical derivatives with stronger activity in future studies on the development of an antiviral against CCHFV., Antiviral Research, 200, art. no. 105276; 2022},
 title = {A screen of FDA-approved drugs with minigenome identified tigecycline as an antiviral targeting nucleoprotein of CrimeanCongo hemorrhagic fever virus},
 volume = {200},
 year = {2022}
}